Synmosa Biopharma - Asset Resilience Ratio
Synmosa Biopharma (4114) has an Asset Resilience Ratio of 7.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Synmosa Biopharma to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Synmosa Biopharma's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Synmosa Biopharma asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Synmosa Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Synmosa Biopharma (4114) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.04 Billion | 7.44% |
| Total Liquid Assets | NT$1.04 Billion | 7.44% |
Asset Resilience Insights
- Limited Liquidity: Synmosa Biopharma maintains only 7.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Synmosa Biopharma Industry Peers by Asset Resilience Ratio
Compare Synmosa Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Synmosa Biopharma (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Synmosa Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.44% | NT$1.04 Billion ≈ $32.77 Million |
NT$13.99 Billion ≈ $440.61 Million |
+1.75pp |
| 2024-12-31 | 5.68% | NT$699.34 Million ≈ $22.03 Million |
NT$12.30 Billion ≈ $387.65 Million |
-0.59pp |
| 2023-12-31 | 6.28% | NT$736.33 Million ≈ $23.20 Million |
NT$11.73 Billion ≈ $369.51 Million |
+3.32pp |
| 2022-12-31 | 2.96% | NT$331.68 Million ≈ $10.45 Million |
NT$11.20 Billion ≈ $352.94 Million |
+1.75pp |
| 2021-12-31 | 1.21% | NT$124.96 Million ≈ $3.94 Million |
NT$10.32 Billion ≈ $325.04 Million |
+0.18pp |
| 2020-12-31 | 1.03% | NT$107.01 Million ≈ $3.37 Million |
NT$10.38 Billion ≈ $326.95 Million |
-0.17pp |
| 2019-12-31 | 1.20% | NT$105.00 Million ≈ $3.31 Million |
NT$8.73 Billion ≈ $275.04 Million |
+1.14pp |
| 2018-12-31 | 0.07% | NT$5.05 Million ≈ $159.10K |
NT$7.54 Billion ≈ $237.70 Million |
-0.37pp |
| 2017-12-31 | 0.44% | NT$32.86 Million ≈ $1.04 Million |
NT$7.50 Billion ≈ $236.41 Million |
-0.01pp |
| 2016-12-31 | 0.45% | NT$30.52 Million ≈ $961.64K |
NT$6.79 Billion ≈ $213.90 Million |
-- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, gr… Read more